Skip to Content
Learn about Adcetris a treatment of Hodgkin Lymphoma

Drug interactions between Nexavar and Stivarga

Results for the following 2 drugs:
Nexavar (sorafenib)
Stivarga (regorafenib)

Interactions between your drugs

There were no interactions found in our database between Nexavar and Stivarga - however, this does not necessarily mean no interactions exist. Always consult with your doctor or pharmacist.

Nexavar

A total of 453 drugs are known to interact with Nexavar.

Stivarga

A total of 274 drugs are known to interact with Stivarga.

Drug and food interactions

Moderate

SORAfenib food

Applies to: Nexavar (sorafenib)

You may experience reduced absorption of SORAfenib in the presence of food. Take SORAfenib on an empty stomach 1 hour before or 2 hours after a meal unless otherwise directed by your doctor. This will make it easier for your body to absorb the medication.

Switch to professional interaction data

Moderate

regorafenib food

Applies to: Stivarga (regorafenib)

Depending on the amount of fat, food may help the absorption of regorafenib. You should take it with a low-fat breakfast at the same time everyday to maintain consistent blood levels and effects. Examples of a low-fat breakfast include: 2 slices of white toast with 1 tablespoon of low-fat margarine and 1 tablespoon of jelly, plus 8 ounces of skim milk (319 calories; 8.2 g fat); or 1 cup of cereal, 8 ounces of skim milk, 1 slice of toast with jam, apple juice, and 1 cup of coffee or tea (520 calories; 2 g fat). Avoid consuming grapefruit or grapefruit juice during treatment, as it may alter the blood levels and effects of the medication. Talk to your doctor or pharmacist if you have questions on how to take this or other medications you are prescribed. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Therapeutic duplication warnings

Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.

Duplication

VEGF/VEGFR inhibitors

Therapeutic duplication

The recommended maximum number of medicines in the 'VEGF/VEGFR inhibitors' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'VEGF/VEGFR inhibitors' category:

  • Nexavar (sorafenib)
  • Stivarga (regorafenib)

Note: The benefits of taking this combination of medicines may outweigh any risks associated with therapeutic duplication. This information does not take the place of talking to your doctor. Always check with your healthcare provider to determine if any adjustments to your medications are needed.

Duplication

Multikinase inhibitors

Therapeutic duplication

The recommended maximum number of medicines in the 'multikinase inhibitors' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'multikinase inhibitors' category:

  • Nexavar (sorafenib)
  • Stivarga (regorafenib)

Note: The benefits of taking this combination of medicines may outweigh any risks associated with therapeutic duplication. This information does not take the place of talking to your doctor. Always check with your healthcare provider to determine if any adjustments to your medications are needed.

Drug Interaction Classification

The classifications below are a guideline only. The relevance of a particular drug interaction to a specific patient is difficult to determine using this tool alone given the large number of variables that may apply.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide